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Abstract 
A 42-year-old man with chronic hepatitis C and ulcerative colitis (UC) was referred to our 
hospital in August 2004 because of bloody diarrhea. He was clinically and endoscopically 
diagnosed with flare of UC. After informed consent had been obtained, he was treated 
with PEG-IFN-α-2a. Four weeks after initiation of PEG-IFN therapy, his abdominal 
symptoms gradually subsided. Intracellular cytokine assay revealed that the ratio of T-
helper (Th) 1 (IFN-γ)/Th 2 (IL-4) increased after IFN therapy. Three months after starting 
IFN therapy, colonoscopy revealed a normal mucosal pattern. He was uneventfully 
treated with PEG-IFN-α-2a for one year. When last seen in November 2006, he was still in 
remission of UC. Our intracellular cytokine data suggested that alteration of Th1/Th2 
cytokine balance by IFN is one possible mechanisms of reducing intestinal inflammation 
in patients with UC. In this regard, IFN therapy could be useful for some patients with UC 
refractory to other conventional therapies. 
 
Several clinical trials have been performed to investigate the therapeutic effect and 
safety of IFN on patients with UC. Bargiggia and colleagues reported that IFN-α can be 
safely administered to patients with chronic hepatitis C and inflammatory bowel disease  
Case Rep Gastroenterol 2007;1:157–161 
DOI: 10.1159/000112654 
Published online: December 21, 2007  © 2007 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
158
[1]. Madsen and colleagues also reported that IFN-α 2a treatment resulted in significant 
depression of the disease activity of ulcerative colitis (UC) [2]. On the other hand, 
recombinant IFNβ-1a was safe but not significantly effective for steroid-refractory UC 
[3]. Thus, clinical outcome of treatments with IFN for patients with UC is inconsistent 
depending on the dose, duration of therapy, and types of IFNs. Therefore, the effects of 
IFN-α on patients with UC are still controversial. We report here the case of an UC 
patient with chronic hepatitis C who was successfully treated with PEG-IFN-α-2a. 
Case Report 
A 42-year-old man with HCV was referred to our hospital in August 2004 because of diarrhea and 
bloody stool. Ten years before admission, he had been diagnosed with total UC endoscopically and 
histologically. He had been treated with 3,000 mg mesalazine alone. Physical examination on admission 
showed mild tenderness in the lower abdomen. Colonoscopic examination revealed reddish and 
edematous mucosa with multiple erosions through the entire colon (fig. 1a). Disease activity index 
(Sutherland Index) was scored as 8. Laboratory data showed thrombocytopenia (57,000/mm3), asparate 
aminotransferase (AST) 124 IU/l, alanine aminotransferase (ALT) 110 IU/l, and hepatitis C virus 
(HCV) RNA (genotype Ib) 757 kIU/ml. Liver biopsy revealed liver injury associated with HCV (F3/A2). 
The patient refused both administration of corticosteroid and leukocytapheresis therapy. After 
informed consent had been obtained, he was treated with PEG-IFN-α-2a (90 μg/week) for improving 
both colonic and liver inflammation. Four weeks after initiation of PEG-IFN therapy, his abdominal 
symptoms gradually subsided. We performed intracellular cytokine assay with peripheral CD4 T cells 
before and after IFN therapy. The ratio of T-helper (Th) 1 (IFN-γ)/Th 2 (interleukin (IL)-4) increased 
(40.2) at 4 weeks after IFN therapy compared to that before (27.4) (fig. 2a, b). However, there was no 
significant difference of IL-10 production from CD4 T cells between before and after IFN therapy. 
Three months after starting IFN therapy, colonoscopy revealed normal mucosal pattern (fig. 1b). DAI 
was scored as 2. He was uneventfully treated with PEG-IFN-α-2a for one year. When last seen in 
November 2006, he was still in remission of UC and his laboratory data showed a negative serum HCV-
RNA, which was suggestive of sustained virological response. 
Discussion 
INF-α, through its immunomodulatory function, could have an impact on pathways in 
the immune system [4]. Therefore, the effect of INF-α on the pathophysiology of IBD has 
been focused, because patients with IBD are characterized by imbalance of the Th1/Th2 
cytokine response. 
Previous reports showed that a treatment with INF-α might be a trigger for 
development of Th1-related intestinal disease such as celiac disease and Crohn’s disease, 
because INF-α plays an important role in T cell differentiation towards a Th1 type of 
immune response [5, 6]. Generally, the pathophysiology of UC is associated with a Th2 
phenotype. In this regard, INF-α is considered to have beneficial effects in the treatment 
of diseases characterized by excess Th2 cells such as UC. In fact, several clinical trials with 
IFN seem to be successful in chronic active UC [1, 2]. However, the effect of INF-α on UC 
remains controversial, because of some reports on the provoking onset and exacerbation 
of UC by treatment of INF-α [7–9]. 
In this case, we evaluated the change of Th1/Th2 ratio of CD4 T cells before and after 
INF-α therapy. The data on intracellular cytokine assay clearly demonstrated that IFN 
administration increased Th1/Th2 ratio of peripheral CD4 T cells, which was suggestive 
of shifting cytokine profile toward Th1. In addition, our data showed that administration 
of PEG-IFN-α-2a did not increase IL-10 production from peripheral CD4 T cells. Many 
mechanisms of effect of IFN therapy on patients with UC have been speculated. Judging 
from our clinical data, alteration of Th1/Th2 cytokine balance is possible. Thus, alteration  
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of Th1/Th2 cytokine balance of peripheral CD4 T cells may be a biomarker for type 1 
interferon therapy in patients with UC. 
In the future, IFN therapy could be useful for patients with UC refractory to other 
conventional therapies by practical application of this biomarker. 
 
 
 
 
 
Fig. 1. a Colonoscopic finding before PEG-IFN-α-2a administration showing reddish and edematous 
mucosa with multiple erosions through the entire colon. b Colonoscopic finding three months after 
PEG-IFN-α-2a administration showing normal colonic appearance. 
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Fig. 2. Comparison of Th1/Th2 ratio of peripheral CD4+ T cells before (a) and after PEG-IFN-α-2a 
administration (b). Flow cytometric analysis showing peripheral IFN-γ and IL-4 CD4 T cells. Plots 
showed IL-4-PE on the y-axis and IFN-γ on the x-axis. 
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